|
Tebentafusp Clinical Trials
8 actively recruiting trials across 7 locations
No change since June 2026
Also known as: Kimmtrak, Tebentafusp-tebn
Pipeline
Phase 1: 1Phase 2: 5Phase 3: 2
Top Sponsors
- University of Miami1
- Sarcoma Alliance for Research through Collaboration1
- Immunocore Ltd1
- H. Lee Moffitt Cancer Center and Research Institute1
- Grupo Español Multidisciplinar de Melanoma1
Indications
- Cancer8
- Metastatic Uveal Melanoma2
- Uveal Melanoma2
- Liver Disease1
- Metastatic Uveal Melanoma in the Liver1
Other1 trial
Birmingham, Alabama1 trial
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
University of Alabama
Phase 1
Phoenix, Arizona1 trial
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Mayo Clinic Arizona
Phase 3
Los Angeles, California1 trial
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
University of Southern California - Norris Cancer Center
Phase 2
Aurora, Colorado1 trial
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Colorado Cancer Center
Phase 2
Miami, Florida1 trial
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
University of Miami
Phase 2
Tampa, Florida1 trial
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Moffitt Cancer Center
Phase 2
Lake Success, New York1 trial
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Northwell Health -Center for Advanced Medicine
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.